GenEdit Announces Series A1 Financing

SOUTH SAN FRANCISCO, Calif., January 23, 2024 – GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy® platform for tissue-selective delivery, today announced that it has raised $24 million in a Series A1 financing. Existing investors Eli Lilly, Sequoia Capital, Korea Investment Partners, Woori Venture Partners, DAYLI Partners, KB Investment, IMM Investment and TIMEFOLIO Asset Management are joined by new investors KDB Silicon Valley, Mirae Asset Venture Investment, ACVC, Pathway Partners, LoftyRock Investment, Terra VC, K2 Investment, Dong-A ST, KIMCO and Huons. The funding will support continued development of the NanoGalaxy platform and a pipeline of preclinical therapeutic candidates.

The NanoGalaxy platform includes thousands of chemically distinct hydrophilic nanoparticles (HNPs), each with unique properties making them amenable to targeting different tissues and cell types and carrying diverse genetic medicine payloads. GenEdit has demonstrated in vivo delivery of siRNA, mRNA, and gene editors to the nervous, immune, and other extra-hepatic systems and is pursuing multiple therapeutic areas through internal and partnered programs.

“The bottleneck for developing new genetic medicines continues to be delivery,” said Kunwoo Lee, Ph.D., CEO of GenEdit. “The ability of our HNPs to carry diverse payloads to diverse tissues has the potential to be an enabling technology for genetic medicines.”

About GenEdit, Inc.
At GenEdit, our mission is to develop innovative genetic medicines with targeted in vivo delivery. Our NanoGalaxy® platform of non-viral, non-lipid hydrophilic nanoparticles (HNPs) offer a combination of advantages over other delivery methods, including tissue selectivity, payload flexibility, low immunogenicity, ability to re-dose, and ease of manufacturing. We are leveraging our platform to develop therapeutics for internal and partnered programs. For more information, visit and follow us on LinkedIn.

Corporate: Kunwoo Lee, Ph.D., GenEdit, Inc.,
Media: Jessica Yingling, Ph.D., Little Dog Communications, +1.858.344.8091